Replies to post #530157 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

Hi Viking, that is. It what the 10-Q actually says. The SOW is about building the capacity, the workstreams. The amendment is only to add 1 more workstream than contracted for in April. It is explicitly a prerequisite to advancing their application to approval, which clearly means it was requested by the regulator, likely when they inspected the first line delivered. Now it is purely a matter of replication. Of course you’d build 1 like, the regulator would confirm it meets their requirements before you’d build the next 4, but the discussion/inspection likely led to the regulator assessing that 1 more workstream or line would be appropriate for their application to ultimately be approved. That is the only way to read that as far as I am concerned.

[exwannabe]

according to my biotech sources, the latest SOW has 99% nothing to do with the application for approval.

Per the 10-Q:

for all 6 workstreams that are prerequisites for an application for product approva

Odd that your expert is 99% certain NWBO is submitting false 10-Q claims.